NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
MYELOMA CLINICAL TRIALS - PHASE 1




- Jun 23, 2022
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma


- Jun 10, 2022
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma


- Apr 20, 2022
NCT05338775: Phase 1: Talquetamab and Teclistamab Each with (PD-1) Inhibitor RRMM - (TRIMM-3)


- Apr 3, 2022
NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets


- Mar 1, 2022
NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma


- Mar 1, 2022
NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia


- Mar 1, 2022
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma


- Dec 23, 2021
NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function


- Dec 16, 2021
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma


- Dec 10, 2021
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Multiple Myeloma, Lymphoma, Leukemia


- Dec 1, 2021
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM


- Dec 1, 2021
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM


- Dec 1, 2021
NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL


- Aug 29, 2021
NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma


- Aug 26, 2021
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers


- Aug 24, 2021
NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma


- Aug 22, 2021
NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS


- Aug 9, 2021
NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in RRMM Myeloma - (ProxiMMity-1)


- Aug 6, 2021
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma


- Aug 5, 2021
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM


- Aug 4, 2021
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Multiple Myeloma


- Jun 18, 2021
NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With MM


- Jun 17, 2021
NCT04702425: phase 1: VOB560-MIK665 Combination First in Human Trial in Patients With Hem. Malig.


- Jun 10, 2021
NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma


- Jun 10, 2021
NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis


- Jun 10, 2021
NCT04895410: Phase 1 -IV Lemzoparlimab +/- Oral/IV Dex plus Oral/IV/SC Anti-Myeloma Regimens


- Jun 9, 2021
NCT04864522: Phase 1: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma


- Jun 9, 2021
NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma


- Jun 8, 2021
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma


- Jun 2, 2021
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma


- May 31, 2021
NCT04855929: Phase 1: Safety and Therapeutic Activity of ANV419 in RRMM - ANV419-001


- Dec 30, 2020
NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in RRMM


- Dec 27, 2020
NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma


- Dec 24, 2020
NCT04570631: Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM


- Dec 19, 2020
NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies


- Dec 17, 2020
NCT04634435: Phase 1/2: Auto Memory-like NK Cell + BHV-1100 (Formerly KP1237), Low Dose IL-2 in NDMM


- Dec 17, 2020
NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma


- Dec 15, 2020
NCT04505813: Phase 1- Antigen-specific T Cell Therapy NEXI 002 Relapsed Refractory Multiple Myeloma


- Dec 12, 2020
NCT04093596: Phase 1 - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma (UNIVERSAL)


- Dec 12, 2020
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma


- Dec 11, 2020
NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in RRMM Myeloma (IMMUNICY-1)


- Dec 11, 2020
NCT04398680: Phase 1: Belantamab Mafodotin With Normal & Impaired Hepatic Function (DREAMM 13) RRMM


- Dec 10, 2020
NCT04521335: Phase 1: Study of Disulfiram and Copper Gluconate in Patients With RRMM (Repurpose-1)


- Dec 10, 2020
NCT04557150: Phase 1: Safety and Pharmacokinetics of Escalating Doses of RO7425781 RRMM Myeloma


- Dec 9, 2020
NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

- Dec 9, 2020
NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies


- Dec 9, 2020
NCT04541368: Phase 1: A Study of CS1-targeted CAR-T Cells Therapy for RRMM After BCMA CAR-T Thaerapy